SCHAUMBURG, Ill., Oct. 11, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Zoledronic Acid Injection 5 mg, the generic form of the bisphosphonate Reclast®, in a ready-to-use premix IV bag presentation. As with all products in Sagent's portfolio, Zoledronic Acid features Sagent's PreventIV Measures SM packaging and labeling, designed to help reduce medication errors. "Sagent is pleased to offer our customers Zoledronic Acid Injection 5 mg in an enhanced packaging option, a ready-to-use premix bag, which can help reduce the risk of contamination and reconstitution errors," said Jeffrey M. Yordon, chief executive officer and chairman of the board of Sagent. About Zoledronic Acid Injection 5 mg Zoledronic Acid 5 mg is indicated for the treatment of Paget's disease of bone in men and women. The package insert, available at www.sagentpharma.com , contains the indications, complete side effect profile and prescribing information. About Sagent Pharmaceuticals, Inc. Sagent Pharmaceuticals, Inc., founded in 2006, is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables. Sagent has created a unique global network of resources, comprising rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfills the evolving needs of patients.
CONTACT: INVESTOR CONTACT: Jonathon Singer, Sagent 847-908-1605 firstname.lastname@example.org